StemCell Therapy

Global Field Service Management Software Market report 2020 offers a professional and in-depth study on the current state of the global Field Service Management Software industry along with competitive landscape, Market share and revenue forecast 2026. The report firstly introduced the basics: definitions, classifications, applications, and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on.

Statistical forecasts in the research study are available for the total Field Service Management Software market along with its key segments and development policy. The key segments, their growth prospects, and the new opportunities they present to market players have been mentioned in the report. Moreover, the impact analysis of the latest mergers and acquisition and joint ventures has been included in the report. The report also provides valuable proposals for new project development that can help companies optimize their operations and revenue structure.

The main sources are industry experts from the Field Service Management Software industry, including management organizations, processing organizations, and analytical services providers that address the value chain of industry organizations. We interviewed all major sources to collect and certify qualitative and quantitative information and to determine future prospects. The qualities of this study in the industry experts industry, such as CEO, Vice President, Marketing Director, Technology and Innovation Director, Founder and Key Executives of key core companies and institutions in major Field Service Management Software around the world in the extensive primary research conducted for this study we interviewed to acquire and verify both sides and quantitative aspects.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.prominentmarketresearch.com/inquiry-report/103296

On the basis of types, the Field Service Management Software market is primarily split into:Cloud-basedOn-premises

On the basis of applications, the market covers:BFSIHealthcareEnergy and UtilitiesTelecom and ITConstruction and Real EstateTransportation and Logistics

The Field Service Management Software market can be split based on product types, major applications, and important regions. From raw materials to downstream buyers of this industry will be analyzed scientifically, the feature of product circulation and sales channel will be presented as well. In a word, this report will help you to establish a panorama of industrial development and characteristics of the Field Service Management Software market.

Get Complete Report in your Inbox within 24 hours @ https://www.prominentmarketresearch.com/checkout/103296

Key Points Table of Content:

Chapter 1: Field Service Management Software Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2: Field Service Management Software Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels and Major Downstream Buyers.

Chapter 3: Value Analysis, Production, Growth Rate and Price Analysis by Type of Field Service Management Software.

Chapter 4: Downstream Characteristics, Consumption and Market Share by Application of Field Service Management Software.

Chapter 5: Production Volume, Price, Gross Margin, and Revenue ($) of Field Service Management Software by Regions (2014-2020).

Chapter 6: Field Service Management Software Production, Consumption, Export and Import by Regions (2014-2020).

Chapter 7: Field Service Management Software Market Status and SWOT Analysis by Regions.

Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Field Service Management Software.

Chapter 9: Field Service Management Software Market Analysis and Forecast by Type and Application (2020-2026).

Chapter 10: Market Analysis and Forecast by Regions (2020-2026).

Chapter 11: Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12: Market Conclusion of the Whole Report.

Chapter 13: Appendix Such as Methodology and Data Resources of This Research.

We can also customize this report and provide individual chapters or a region-wise breakdown report such as North America, Europe or Asia. Also, if you have any special requirements, please let us know and we will offer you the report as you want.

About Us

Prominent Market Research has an extensive coverage of diligence verticals of qualitative and quantitative reports across all the industries. In case your needs are not met by syndicated reports untaken by the foremost publishers, we can help you by proposing a customized research elucidation by liaising with different research interventions saving your valuable time and money. We have experienced and trained staff that helps you navigate different options and lets you choose preeminent research solution at most effective cost.

Contact Us

Michael, Sales Manager

Prominent Market Research

7309 Woodward Ave,

Apt 107, Woodridge, Illinois, USA, 60517

Phone: USA +1-630-361-6262

Email: [emailprotected]

Corporate Sales: [emailprotected]

Here is the original post:
Field Service Management Software Market by Key Manufacturers, Regions, Risk Analysis, Industry Share, Driving Factors, Deployment Policy, Innovative...

With so many groundbreaking medical advances being revealed to the world every single day, you would imagine there would be some advancement on the plethora of many female-prevalent diseases (think female cancers, Alzheimer's, depression, heart conditions etc.) that women are fighting every single day.

For Anna Villarreal and her team, there frankly wasn't enough being done. In turn, she developed a method that diagnoses these diseases earlier than traditional methods, using a pretty untraditional method in itself: through your menstrual blood.

Getting from point A to point B wasn't so easy though. Villarreal was battling a disease herself and through that experience. I wondered if there was a way to test menstrual blood for female specific diseases," she says. "Perhaps my situation could have been prevented or at least better managed. This led me to begin researching menstrual blood as a diagnostic source. For reasons the scientific and medical community do not fully understand, certain diseases impact women differently than men. The research shows that clinical trials have a disproportionate focus on male research subjects despite clear evidence that many diseases impact more women than men."

There's also no denying that gap in women's healthcare in clinical research involving female subjects - which is exactly what inspired Villarreal to launch her company, LifeStory Health. She says that, with my personal experience everything was brought full circle."

There is a challenge and a need in the medical community for more sex-specific research. I believe the omission of females as research subjects is putting women's health at risk and we need to fuel a conversation that will improve women's healthcare.,"

-Anna Villarreal

Her brand new biotech company is committed to changing the women's healthcare market through technology, innovation and vocalization and through extensive research and testing. She is working to develop the first ever, non-invasive, menstrual blood diagnostic and has partnered with a top Boston-area University on research and has won awards from The International Society for Pharmaceutical Engineering and Northeastern University's RISE.

How does it work exactly? Proteins are discovered in menstrual blood that can quickly and easily detect, manage and track diseases in women, resulting in diseases that can be earlier detected, treated and even prevented in the first place. The menstrual blood is easy to collect and since it's a relatively unexplored diagnostic it's honestly a really revolutionary concept, too.

So far, the reactions of this innovative research has been nothing but excitement. The reactions have been incredibly positive." she shares with SWAAY. Currently, menstrual blood is discarded as bio waste, but it could carry the potential for new breakthroughs in diagnosis. When I educate women on the lack of female subjects used in research and clinical trials, they are surprised and very excited at the prospect that LifeStory Health may provide a solution and the key to early detection."

To give a doctor's input, and a little bit more of an explanation as to why this really works, Dr. Pat Salber, MD, and Founder of The Doctor Weighs In comments: researchers have been studying stem cells derived from menstrual blood for more than a decade. Stem cells are cells that have the capability of differentiating into different types of tissues. There are two major types of stem cells, embryonic and adult. Adult stem cells have a more limited differentiation potential, but avoid the ethical issues that have surrounded research with embryonic stem cells. Stem cells from menstrual blood are adult stem cells."

These stem cells are so important when it comes to new findings. Stem cells serve as the backbone of research in the field of regenerative medicine the focus which is to grow tissues, such as skin, to repair burn and other types of serious skin wounds.

A certain type of stem cell, known as mesenchymal stem cells (MenSCs) derived from menstrual blood has been found to both grow well in the lab and have the capability to differentiate in various cell types, including skin. In addition to being used to grow tissues, their properties can be studied that will elucidate many different aspects of cell function," Dr. Salber explains.

To show the outpour of support for her efforts and this major girl power research, Villarreal remarks, women are volunteering their samples happily report the arrival of their periods by giving samples to our lab announcing de-identified sample number XXX arrived today!" It's a far cry from the stereotype of when it's that time of the month."

How are these collections being done? Although it might sound odd to collect menstrual blood, plastic cups have been developed to use in the collection process. This is similar to menstrual products, called menstrual cups, that have been on the market for many years," Dr. Salber says.

Equally shocking and innovative, this might be something that becomes more common practice in the future. And according to Dr. Salber, women may be able to not only use the menstrual blood for early detection, but be able to store the stem cells from it to help treat future diseases. Companies are working to commercialize the use of menstrual blood stem cells. One company, for example, is offering a patented service to store menstrual blood stem cells for use in tissue generation if the need arises."

View original post here:
How I Went From Managing Complexity to Becoming a U.S. Ambassador and CEO - SWAAY

The Cryochambers market study added by Market Study Report, LLC, exhibits a comprehensive analysis of the growth trends present in the global business scenario. The study further presents conclusive data referring to the commercialization aspects, industry size and profit estimation of the market. The study also illustrates the competitive standing of leading manufacturers in the projection timeline whilst incorporating their diverse portfolio and regional expansion endeavors.

The Cryochambers market report presents a detailed assessment of the industry vertical and it also elaborates about the dual perspective- production and consumption.

Considering the production aspect, the study provides details regarding the manufacturing of the product, product renumeration, and the gross margins of the firms manufacturing the product. Speaking of the consumption, the report includes data related to the product consumption value and the product consumption volume along with the import and export status of the products.

Request a sample Report of Cryochambers Market at:https://www.marketstudyreport.com/request-a-sample/2450123?utm_source=technologymagazine&utm_medium=Kunal

An overview of the regional landscape:

Regional segmentation: North America, Europe, Asia Pacific, Middle East & Africa, Latin America.

Details mentioned in this section

The report offers an in-depth assessment of the regional territory of this industry.

Data provided in the study:

An overview of the product spectrum:

Product segmentation:

Details mentioned in this section

The report evaluates data with regards to the product reach.

Data provided in the study:

An idea of the application terrain:

Application segmentation:

Details mentioned in this section

Reports can be segmented with respect to the application spectrum.

Ask for Discount on Cryochambers Market Report at:https://www.marketstudyreport.com/check-for-discount/2450123?utm_source=technologymagazine&utm_medium=Kunal

Data provided in the study:

An idea of the competitive reach:

Competitive segmentation:

Details mentioned in this section

Report provides details related to the competitive spectrum of the Cryochambers market.

Data provided in this section:

The report provides data relating growth margins of these firms along with the product costs, renumeration, and manufacturing expenses.

It also provides data that reveals the extent to which the industry has been evaluated. Also, the report contains data about the analysis of the feasibility of the new investment projects that have commenced along with the research conclusions inferred from the studies.

For More Details On this Report:https://www.marketstudyreport.com/reports/global-cryochambers-market-research-report-2020-segment-by-key-companies-countries-types-applications-and-forecast-2021-to-2026

Some of the Major Highlights of TOC covers:

Development Trend of Analysis of Cryochambers Market

Marketing Channel

Market Dynamics

Methodology/Research Approach

Related Reports:

1. Global Opthalmology Drugs and Devices Market Research Report 2020, Segment by Key Companies, Countries, Types, Applications and Forecast 2021 to 2026Opthalmology Drugs and Devices market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability. The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market.Read More: https://www.marketstudyreport.com/reports/global-opthalmology-drugs-and-devices-market-research-report-2020-segment-by-key-companies-countries-types-applications-and-forecast-2021-to-2026

2. Global Metastatic Cancer Treatment Market Research Report 2020, Segment by Key Companies, Countries, Types, Applications and Forecast 2021 to 2026Metastatic Cancer Treatment Market report characterize imperative Portion and contenders of the market regarding market estimate, volume, esteem. This report likewise covers every one of the locales and nations of the world, which demonstrates a territorial improvement status, it additionally incorporates Business Profile, Introduction, Revenue and so on.Read More: https://www.marketstudyreport.com/reports/global-metastatic-cancer-treatment-market-research-report-2020-segment-by-key-companies-countries-types-applications-and-forecast-2021-to-2026

Read More Reports On: https://www.marketwatch.com/press-release/furniture-market-trends-2019-industry-analysis-top-manufacturers-application-opportunities-forecast-to-2024-2020-01-08

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

The rest is here:
Cryochambers Market Analysis, Size, Regional Outlook, Competitive Strategies and Forecasts to 2026 - Technology Magazine

Sorry Mom and Dad: It turns out you might not have been exaggerating when you told us your children made your hair turn gray.

Stress may play a key role in just how quickly hair goes from colored to ashen, a study published this past week in the journal Nature suggests.

Scientists have long understood some link is possible between stress and gray hair, but this new research from Harvard University in Massachusetts more deeply probes the exact mechanisms at play.

The researchers initial tests looked closely at cortisol, the stress hormone that surges in the body when a person experiences a fight or flight response.

Its an important bodily function, but the long-term presence of heightened cortisol is linked to a host of negative health outcomes.

But the culprit ended up being a different part of the bodys fight or flight response the sympathetic nervous system.

These nerves are all over the body, including making inroads to each hair follicle, the researchers reported.

Chemicals released during the stress response specifically norepinephrine causes pigment producing stem cells to activate prematurely, depleting the hairs reserves of color.

The detrimental impact of stress that we discovered was beyond what I imagined, Ya-Chieh Hsu, PhD, a lead study author and an associate professor of stem cell and regenerative biology at Harvard, said in a press release. After just a few days, all of the pigment-regenerating stem cells were lost. Once theyre gone, you cant regenerate pigments anymore. The damage is permanent.

But stress isnt the only or even the primary reason that most people get gray hair.

In most cases, its simple genetics.

Gray hair is caused by loss of melanocytes (pigment cells) in the hair follicle. This happens as we age and, unfortunately, there is no treatment that can restore these cells and the pigment they produce, melanin, Dr. Lindsey A. Bordone, a dermatologist at ColumbiaDoctors and an assistant professor of dermatology at Columbia University Medical Center in New York, told Healthline. Genetic factors determine when you go gray. There is nothing that can be done medically to prevent this from happening when it is genetically predetermined to happen.

That doesnt mean environmental factors such as stress dont play a role.

Smoking, for instance, is a known risk factor for premature graying, according to a 2013 study. So kick the habit if you want to keep that color a little longer.

Other contributing factors to premature graying include deficiencies in protein, vitamin B-12, copper, and iron as well as aging due in part to an accumulation of oxidative stress.

That stress is prompted by an imbalance between free radicals and antioxidants in your body that can damage tissue, proteins, and DNA, Kasey Nichols, NMD, an Arizona physician and a health expert at Rave Reviews, told Healthline.

And some degree of oxidative stress is a natural part of life.

We would expect increasing gray hair as we advance in age, and we see about a 10 percent increase in the chance of developing gray hair for every decade after age 30, Nichols said.

Changes you can pursue to delay premature grays include eating a diet high in omega-3 fatty acids such as walnuts and fatty fish, not spending too much time in the skin-damaging and hair-damaging ultraviolet light of the sun, and taking vitamin B-12 and vitamin B-6 supplements.

That said, if you are going gray prematurely, it wouldnt hurt to go have a checkup just in case natural genetic factors arent the sole culprit.

The new Harvard research is only a mouse study, so replicating the same results in a human study would be necessary to strengthen the findings.

But the Harvard research has implications far beyond graying hair, with the hair color change merely one obvious sign of other internal changes as a result of prolonged stress.

By understanding precisely how stress affects stem cells that regenerate pigment, weve laid the groundwork for understanding how stress affects other tissues and organs in the body, said Hsu. Understanding how our tissues change under stress is the first critical step towards eventual treatment that can halt or revert the detrimental impact of stress.

Might that also mean someday halting and reverting the march of premature gray hair? Its too soon to tell.

We still have a lot to learn in this area, Hsu said.

See more here:
Scientists Think They Know How Stress Causes Gray Hair - Healthline

When Marie Antoinette was captured during the French Revolution, her hair reportedly turned white overnight. In more recent history, former U.S. Senator John McCain experienced severe injuries as a prisoner during the Vietnam Warand lost color in his hair.

For a long time, anecdotes have connected stressful experiences with hair-graying.

Get more HMS news here

Now, for the first time, Harvard University scientists have discovered exactly how the process plays out: stress activates nerves that are part of the fight-or-flight response, which in turn cause permanent damage to pigment-regenerating stem cells in hair follicles.

The work, published inNature, details the molecular mechanisms behind the longstanding biological puzzle.

Everyone has an anecdote to share about how stress affects their body, particularly in their skin and hairthe only tissues we can see from the outside, said senior authorYa-Chieh Hsu, the Alvin and Esta Star Associate Professor of Stem Cell and Regenerative Biology at Harvard. We wanted to understand if this connection is true, and if so, how stress leads to changes in diverse tissues. Hair pigmentation is such an accessible and tractable system to start with, and besides, we were genuinely curious to see if stress indeed leads to hair-graying.

Fingering the culprit

Because stress affects the whole body, researchers first had to narrow down which body system was responsible for connecting stress to hair color. The team first hypothesized that stress causes an immune attack on pigment-producing cells. However, when mice lacking immune cells still showed hair-graying, researchers turned to the hormone cortisol. Once more, it was a dead end.

Stress always elevates levels of the hormone cortisol in the body, so we thought that cortisol might play a role, Hsu said. But surprisingly, when we removed the adrenal gland from the mice so that they couldnt produce cortisol-like hormones, their hair still turned gray under stress.

After systematically eliminating different possibilities, researchers homed in on the sympathetic nervous system, which is responsible for the bodys fight-or-flight response.

Sympathetic nerves branch out into each hair follicle on the skin. The researchers found that stress causes these nerves to release the chemical norepinephrine, which gets taken up by nearby pigment-regenerating stem cells.

Permanent damage

In the hair follicle, certain stem cells act as a reservoir of pigment-producing cells. When hair regenerates, some of the stem cells convert into pigment-producing cells that color the hair.

Researchers found that the norepinephrine from sympathetic nerves causes the stem cells to activate excessively. The stem cells all convert into pigment-producing cells, prematurely depleting the reservoir.

When we started to study this, I expected that stress was bad for the body, but the detrimental impact of stress that we discovered was beyond what I imagined, Hsu said. After just a few days, all of the pigment-regenerating stem cells were lost. Once theyre gone, you cant regenerate pigments anymore. The damage is permanent.

The finding underscores the negative side effects of an otherwise protective evolutionary response, the researchers said.

Acute stress, particularly the fight-or-flight response, has been traditionally viewed to be beneficial for an animals survival. But in this case, acute stress causes permanent depletion of stem cells, said postdoctoral fellow Bing Zhang, the lead author of the study.

Answering a fundamental question

To connect stress with hair-graying, the researchers started with a whole-body response and progressively zoomed into individual organ systems, cell-to-cell interaction and, eventually, all the way down to molecular dynamics. The process required a variety of research tools along the way, including methods to manipulate organs, nerves and cell receptors.

To go from the highest level to the smallest detail, we collaborated with many scientists across a wide range of disciplines, using a combination of different approaches to solve a very fundamental biological question, Zhang said.

One of the study collaborators wasIsaac Chiu, assistant professor of immunology in the Blavatnik Institute at Harvard Medical School, who studies the interplay between the nervous and immune systems.

We know that peripheral neurons powerfully regulate organ function, blood vessels and immunity, but less is known about how they regulate stem cells, Chiu said.With this study, we now know that neurons can control stem cells and their function and can explain how they interact at the cellular and molecular levels to link stress with hair-graying.

The findings can help illuminate the broader effects of stress on various organs and tissues. This understanding will pave the way for new studies that seek to modify or block the damaging effects of stress.

By understanding precisely how stress affects stem cells that regenerate pigment, weve laid the groundwork for understanding how stress affects other tissues and organs in the body, Hsu said. Understanding how our tissues change under stress is the first critical step towards eventual treatment that can halt or revert the detrimental impact of stress. We still have a lot to learn in this area.

More:
Research details the link between stress and gray... - ScienceBlog.com

Every year, medical technology further evolves, and new discoveries are made. This brings hope to those suffering from grave medical conditions. Health24 covers these advances on an ongoing basis, and the following are a few of the biggest breakthroughs of the decade in a nutshell:

The past decade has seen a number of medical headlines involving 3D-organ-printing, up to the point where, recently, researchers managed to create living skin, complete with blood vessels, as well as hearts. While many of these advancements need more research before they can be used in a clinical setting, 3D-printing is set to become more prevalent over the next the next decade, which will make transplanting easier for those in need.

Health24 published several stories about gene therapy over the last ten years. And while there were restrictions placed on gene therapy research in the early 2000s, there's been a strong resurgence, as illustrated by this study focusing on gene therapy in the fight against leukaemia.

Despite a number of setbacks, there were some successes that could translate to treatments in the future. One of the most recent development involves the first clinical trial of its type. Researchers used CRISPR to edit the DNA of peoples immune systems to help treat certain cancers.

While only a small number of patients were involved in the Stage 1 clinical trial, experts believe that this was an important step, in that it proved that the technique is safe to use.

Read more about gene therapy here.

The focus on gut health and our microbiome (the collection of bacteria in the gut) has never been stronger. In the past, researchers didnt pay much attention to the role of the bacteria in our gut, and it's been mainly during the past 15 years that researchers have been studying this concept.

According to the BMJ, the gut microbiota is crucial for essential processes in the body, such as the fermentation of non-digestible dietary fibres. It does more than that, though, and plays a role in many key areas of human health, from our immunity and appetite to the way we digest our food.

This helped researchers to explore the role of gut bacteria in areas like depression. An article in the BMJ reports on changes in the gut microbiota in the case of not only obesity, diabetes, and liver disease, but also cancer and even neurodegenerative diseases.

In fact, a study covered by Health24 links gut microbes to chronic fatigue syndrome, a condition that has been baffling experts for decades.

HIV and Aids remain important public healthcare topics in South Africa. During the past decade, antiretroviral treatment has improved and become more readily available. In fact, the virus is currently controlled so well that the viral load in many patients' blood has become virtually undetectable.

According to Pharmaceutical Technologies, various studies over the past decade found that treatment with antiretroviral therapy has also reduced the risk of spreading the infection to HIV-negative partners in both homosexual and heterosexual couples.

A few months ago, Health24 published a story about a man simply known as the London patient, who became entirely free from HIV following stem cell treatment for Hodgkin's Lymphoma. He was the second patient to demonstrate this phenomenon.

In 2017, a man known as the Berlin patient had two copies of the CCR5-delta32 genetic mutation. The patient stopped his ART 16 months following a bone marrow transplant, and his blood viral load was still undetectable 18 months later.

Canceris one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases reported annually, according to the World Health Organization. Experts say immunotherapy is a promising new development, and ongoing research has been conducted over the past decade.

In one of the latest studies, Dr Christopher E. Rudd, a researcher at the Centre de Recherche de l'Hpital Maisonneuve-Rosemont (CR-HMR) and Universit de Montral, discovered a new cell therapy approach that boosts the immune response of T lymphocytes to malignant tumours. The results of the study were recently published in the respected journal Nature.

Image credit: iStock

Compiled by Marelize Wilke

Read the original:
5 of the biggest medical advances of the past decade - Health24

With so many groundbreaking medical advances being revealed to the world every single day, you would imagine there would be some advancement on the plethora of many female-prevalent diseases (think female cancers, Alzheimer's, depression, heart conditions etc.) that women are fighting every single day.

For Anna Villarreal and her team, there frankly wasn't enough being done. In turn, she developed a method that diagnoses these diseases earlier than traditional methods, using a pretty untraditional method in itself: through your menstrual blood.

Getting from point A to point B wasn't so easy though. Villarreal was battling a disease herself and through that experience. I wondered if there was a way to test menstrual blood for female specific diseases," she says. "Perhaps my situation could have been prevented or at least better managed. This led me to begin researching menstrual blood as a diagnostic source. For reasons the scientific and medical community do not fully understand, certain diseases impact women differently than men. The research shows that clinical trials have a disproportionate focus on male research subjects despite clear evidence that many diseases impact more women than men."

There's also no denying that gap in women's healthcare in clinical research involving female subjects - which is exactly what inspired Villarreal to launch her company, LifeStory Health. She says that, with my personal experience everything was brought full circle."

There is a challenge and a need in the medical community for more sex-specific research. I believe the omission of females as research subjects is putting women's health at risk and we need to fuel a conversation that will improve women's healthcare.,"

-Anna Villarreal

Her brand new biotech company is committed to changing the women's healthcare market through technology, innovation and vocalization and through extensive research and testing. She is working to develop the first ever, non-invasive, menstrual blood diagnostic and has partnered with a top Boston-area University on research and has won awards from The International Society for Pharmaceutical Engineering and Northeastern University's RISE.

How does it work exactly? Proteins are discovered in menstrual blood that can quickly and easily detect, manage and track diseases in women, resulting in diseases that can be earlier detected, treated and even prevented in the first place. The menstrual blood is easy to collect and since it's a relatively unexplored diagnostic it's honestly a really revolutionary concept, too.

So far, the reactions of this innovative research has been nothing but excitement. The reactions have been incredibly positive." she shares with SWAAY. Currently, menstrual blood is discarded as bio waste, but it could carry the potential for new breakthroughs in diagnosis. When I educate women on the lack of female subjects used in research and clinical trials, they are surprised and very excited at the prospect that LifeStory Health may provide a solution and the key to early detection."

To give a doctor's input, and a little bit more of an explanation as to why this really works, Dr. Pat Salber, MD, and Founder of The Doctor Weighs In comments: researchers have been studying stem cells derived from menstrual blood for more than a decade. Stem cells are cells that have the capability of differentiating into different types of tissues. There are two major types of stem cells, embryonic and adult. Adult stem cells have a more limited differentiation potential, but avoid the ethical issues that have surrounded research with embryonic stem cells. Stem cells from menstrual blood are adult stem cells."

These stem cells are so important when it comes to new findings. Stem cells serve as the backbone of research in the field of regenerative medicine the focus which is to grow tissues, such as skin, to repair burn and other types of serious skin wounds.

A certain type of stem cell, known as mesenchymal stem cells (MenSCs) derived from menstrual blood has been found to both grow well in the lab and have the capability to differentiate in various cell types, including skin. In addition to being used to grow tissues, their properties can be studied that will elucidate many different aspects of cell function," Dr. Salber explains.

To show the outpour of support for her efforts and this major girl power research, Villarreal remarks, women are volunteering their samples happily report the arrival of their periods by giving samples to our lab announcing de-identified sample number XXX arrived today!" It's a far cry from the stereotype of when it's that time of the month."

How are these collections being done? Although it might sound odd to collect menstrual blood, plastic cups have been developed to use in the collection process. This is similar to menstrual products, called menstrual cups, that have been on the market for many years," Dr. Salber says.

Equally shocking and innovative, this might be something that becomes more common practice in the future. And according to Dr. Salber, women may be able to not only use the menstrual blood for early detection, but be able to store the stem cells from it to help treat future diseases. Companies are working to commercialize the use of menstrual blood stem cells. One company, for example, is offering a patented service to store menstrual blood stem cells for use in tissue generation if the need arises."

See the original post:
What I Learned About Marriage as a Survivor of Abuse - SWAAY

When Marie Antoinette was captured during the French Revolution, her hair reportedly turned white overnight. In more recent history, John McCain experienced severe injuries as a prisoner of war during the Vietnam War and lost color in his hair.

For a long time, anecdotes have connected stressful experiences with the phenomenon of hair graying. Now, for the first time, Harvard University scientists have discovered exactly how the process plays out: stress activates nerves that are part of the fight-or-flight response, which in turn cause permanent damage to pigment-regenerating stem cells in hair follicles.

The study, published in Nature, advances scientists knowledge of how stress can impact the body.

Everyone has an anecdote to share about how stress affects their body, particularly in their skin and hair the only tissues we can see from the outside, said senior author Ya-Chieh Hsu, the Alvin and Esta Star Associate Professor of Stem Cell and Regenerative Biology at Harvard. We wanted to understand if this connection is true, and if so, how stress leads to changes in diverse tissues. Hair pigmentation is such an accessible and tractable system to start with and besides, we were genuinely curious to see if stress indeed leads to hair graying.

Narrowing down the culprit

Because stress affects the whole body, researchers first had to narrow down which body system was responsible for connecting stress to hair color. The team first hypothesized that stress causes an immune attack on pigment-producing cells. However, when mice lacking immune cells still showed hair graying, researchers turned to the hormone cortisol. But once more, it was a dead end.

Stress always elevates levels of the hormone cortisol in the body, so we thought that cortisol might play a role, Hsu said. But surprisingly, when we removed the adrenal gland from the mice so that they couldnt produce cortisol-like hormones, their hair still turned gray under stress.

After systematically eliminating different possibilities, researchers honed in on the sympathetic nerve system, which is responsible for the bodys fight-or-flight response.

Sympathetic nerves branch out into each hair follicle on the skin. The researchers found that stress causes these nerves to release the chemical norepinephrine, which gets taken up by nearby pigment-regenerating stem cells.

Permanent damage

In the hair follicle, certain stem cells act as a reservoir of pigment-producing cells. When hair regenerates, some of the stem cells convert into pigment-producing cells that color the hair.

Researchers found that the norepinephrine from sympathetic nerves causes the stem cells to activate excessively. The stem cells all convert into pigment-producing cells, prematurely depleting the reservoir.

When we started to study this, I expected that stress was bad for the body but the detrimental impact of stress that we discovered was beyond what I imagined, Hsu said. After just a few days, all of the pigment-regenerating stem cells were lost. Once theyre gone, you cant regenerate pigment anymore. The damage is permanent.

The finding underscores the negative side effects of an otherwise protective evolutionary response, the researchers said.

Acute stress, particularly the fight-or-flight response, has been traditionally viewed to be beneficial for an animals survival. But in this case, acute stress causes permanent depletion of stem cells, said postdoctoral fellow Bing Zhang, the lead author of the study.

Answering a fundamental question

To connect stress with hair graying, the researchers started with a whole-body response and progressively zoomed into individual organ systems, cell-to-cell interaction and, eventually, all the way down to molecular dynamics. The process required a variety of research tools along the way, including methods to manipulate organs, nerves, and cell receptors.

To go from the highest level to the smallest detail, we collaborated with many scientists across a wide range of disciplines, using a combination of different approaches to solve a very fundamental biological question, Zhang said.

The collaborators included Isaac Chiu, assistant professor of immunology at Harvard Medical School who studies the interplay between nervous and immune systems.

We know that peripheral neurons powerfully regulate organ function, blood vessels, and immunity, but less is known about how they regulate stem cells, Chiu said.

With this study, we now know that neurons can control stem cells and their function, and can explain how they interact at the cellular and molecular level to link stress with hair graying.

The findings can help illuminate the broader effects of stress on various organs and tissues. This understanding will pave the way for new studies that seek to modify or block the damaging effects of stress.

By understanding precisely how stress affects stem cells that regenerate pigment, weve laid the groundwork for understanding how stress affects other tissues and organs in the body, Hsu said. Understanding how our tissues change under stress is the first critical step towards eventual treatment that can halt or revert the detrimental impact of stress. We still have a lot to learn in this area.

The study was supported by the Smith Family Foundation Odyssey Award, the Pew Charitable Trusts, Harvard Stem Cell Institute, Harvard/MIT Basic Neuroscience Grants Program, Harvard FAS and HMS Deans Award, American Cancer Society, NIH, the Charles A. King Trust Postdoctoral Fellowship Program, and an HSCI junior faculty grant.

Read more from the original source:
Researchers uncover link between the nervous system - Tdnews

First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab in combination with carboplatin

Second patient with stage 4 HER2+ metastatic breast cancer (MBC) shows 50 percent shrinkage in the primary tumor and no new signs of metastasis in the brain after treatment with leronlimab as a monotherapy

VANCOUVER, Washington, Jan. 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (CytoDyn or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today additional promising results from its clinical trials evaluating leronlimab for the treatment of metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC).

New data from the first patient enrolled in the Companys metastatic triple-negative breast (mTNBC) Phase 1b/2 trial continues to show no detectable levels of circulating tumor cells (CTC) or putative metastatic cells in the peripheral blood following 15 weeks of treatment with leronlimab in combination with carboplatin.

The second patient, enrolled through an emergency investigational new drug (IND) with stage 4 HER2+ MBC that has metastasized to the liver, lung and brain, showed a 50 percent shrinkage of the primary tumor and no new metastasis in the brain after treatment with leronlimab as a monotherapy. The patient was previously treated with pertuzumab and trastuzumab for over a year and a half. This patient has been taking leronlimab since November 25, 2019 with one 700 mg dose each week.

Recent testing of the first patient demonstrated continued absence of CTCs in all blood tubes with only one cancer-associated macrophage like cells (CAMLs) in one of two tubes. In the second patient, the follow up brain scan conducted on January 17, 2020, showed that the largest brain lesion had a greater than 4-fold reduction in size, said Bruce Patterson, M.D., chief executive officer and founder of IncellDx, a diagnostic partner and an advisor to CytoDyn. Other smaller lesions on the second patients brain have not changed in size and cerebral edema remains at decreased levels since the last imaging studies. Taken together, these results suggest continued response of both primary and metastatic tumors to treatment with leronlimab for both the first and second patient.

Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn, added: We are thrilled to see these additional data that further support leronlimab as a potential treatment option for patients with mTNBC and MBC. As a Company, we look forward to continuing our work in the oncology space and developing a potentially safe and effective treatment option for patients suffering from this deadly disease.

About Triple-Negative Breast CancerTriple-negative breast cancer (TNBC) is a type of breast cancer characterized by the absence of the three most common types of receptors in the cancer tumor known to fuel most breast cancer growthestrogen receptors (ER), progesterone receptors (PR) and the hormone epidermal growth factor receptor 2 (HER-2) gene.1TNBC cancer occurs in about 10 to 20 percent of diagnosed breast cancers and can be more aggressive and more likely to spread and recur.2,3Since the triple negative tumor cells lack these receptors, common treatments for breast cancer such as hormone therapy and drugs that target estrogen, progesterone, and HER-2 are ineffective.4Currently, there are no targeted therapies approved to treat triple negative breast cancer.5

About Leronlimab (PRO 140)The U.S. Food and Drug Administration (FDA) have granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including NASH. Leronlimab has successfully completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients).

Story continues

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 plays an important role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is therefore conducting aPhase 2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019. Additional research is being conducted with leronlimab in the setting of cancer and NASH with plans to conduct additionalclinical studies when appropriate.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation and may be important in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab (PRO 140) as a once-weekly monotherapy for HIV-infected patients and, plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab (PRO 140) can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.

Forward-Looking StatementsThis press releasecontains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i)the sufficiency of the Companys cash position, (ii)the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv)the Companys ability to enter into partnership or licensing arrangements with third parties, (v)the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi)the Companys ability to achieve approval of a marketable product, (vii)the design, implementation and conduct of the Companys clinical trials, (viii)the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix)the market for, and marketability of, any product that is approved, (x)the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii)general economic and business conditions, (xiii)changes in foreign, political, and social conditions, and (xiv)various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form10-K, and any risk factors or cautionary statements included in any subsequent Form10-Q or Form8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CONTACTSMedia:Grace FotiadesLifeSci Communicationsgfotiades@lifescicomms.com (646) 876-5026

Investors: Nader Pourhassan, Ph.D.President & CEOnpourhassan@cytodyn.com

View post:
Impressive Results Continue from CytoDyns Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC - Yahoo Finance

LAS VEGAS, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (Zhittya or the Company), has signed a $151.5 million USD international marketing partnership agreement with Regenerative Medicine of Latin America, Inc. for the exclusive rights to market and sell all biological drugs developed by Zhittya during a 30-year time period. The payments include an initial upfront payment valued at $76.5 million with the additional $75 million to be amortized through future milestone payments.

Zhittya is developing a family of biological drugs to treat diseases which are characterized by diminished blood flow, or perfusion, to specific tissues or organs. The diseases Zhittyas drugs are intended to treat address a variety of disorders and diseases, including: coronary heart disease, diabetic foot ulcers, stroke recovery, Parkinsons disease (PD), Alzheimers disease, and 14 additional major medical disorders characterized by insufficient blood perfusion.

According to the American Heart Associations 2019 Statistics at a Glance, heart disease is responsible for the death of approximately one out of three U.S. adults. In a U.S. Food and Drug Administration (FDA) clinical trial, Zhittyas heart-specific drug treatment demonstrated a successful triggering of new blood vessel growth in a diseased heart. According to a 2017 report by the World Health Organization, there are an estimated 20 million people who suffer from heart disorders in Latin America alone, 80% of which suffer from a particularly notorious form called small vessel disease, a disease that only Zhittyas drug has been able to address; the standard forms of treatment for coronary artery disease, including bypass and stenting procedures, can only be performed on larger arteries.

Our portfolio of drugs seeks to address diseases which directly cause the suffering and even death of over 50% of all adults, said Zhittya CEO Daniel C. Montano. In addition to the territories covered by our existing partnerships in North America, Europe and China, Latin America is particularly impacted by heart disease due to a variety of health and environmental concerns in the region. This agreement with Regenerative Medicine of Latin America is another major step forward to treating heart disease in Latin America and globally. Going forward, we believe we are on the path to a number of other major medical breakthroughs to address even more diseases caused by a lack of blood perfusion.

Dr. Jack Jacobs, President of Zhittya Genesis Medicine, stated, Our drug currently being developed to treat Parkinsons disease has demonstrated encouraging results with impressive outcomes in preclinical models of Parkinsons disease in rodents and primates. This drug has the potential to be a disease modifying agent; in preclinical studies it was shown to reverse the decline and actually stimulate the regeneration of dopamine-producing neurons, the root cause of Parkinsons disease in patients. According to a recent report from the Cleveland Clinic, the incidence rate of Parkinsons disease per 100,000 people was highest in Hispanics. We believe our drug can have a tremendous impact in this region in addition to our existing partnerships both domestically and internationally.

Dr. Jacobs added, We have filed applications and are advancing through the approval process to initiate Phase I clinical trials in Mexico for Parkinsons disease. We are also pursuing a second medical indication for patients with amyotrophic lateral sclerosis (ALS). It is our goal to be in a position to begin dosing patients with Parkinsons disease and ALS by early 2020, which should enable us to learn if our drug has the same beneficial effects in humans as it demonstrated in animals. These clinical trials that will hopefully begin very soon in Mexico will drive intense attention and interest to Regenerative Medicine of Latin America.

About Zhittya Genesis MedicineZhittya Genesis Medicine, Inc. is advancing a group of drugs which trigger the human bodys natural regeneration process. Our medicine initiates a biological response in the human body referred to as therapeutic angiogenesis, which will only occur in diseased tissues that become ischemic due to a lack of blood flow. In those areas with insufficient blood flow, the drug stimulates growth of new blood vessels, providing nourishment and removing metabolic waste products, thereby re-establishing normal cellular functions. Heart disease, stroke, peripheral artery disease (PAD) and diabetic foot ulcers are just some of the disorders the drugs can treat. Currently, over 75 human diseases are known to be caused by lack of blood flow to a tissue or organ. The Companys management has been working to advance its proprietary medicines for over 21 years and has expended in excess of $140 million USD to date in support of these efforts. To learn more, please visitzhittyaregenerativemedicine.com

About Regenerative Medicine of Latin AmericaRegenerative Medicine of Latin America, Inc. owns the 30-year exclusive rights to market and sell all drugs developed by Zhittya for the territories of Mexico and all Latin American countries south of Mexico. These areas encompass a population of over 600 million people. In addition to its vast population, Latin America also has some of the worlds highest rates of diabetes, heart disease, strokes and other diseases brought on by vascular dysfunction.

Zhittya Contact:

Daniel C. Montano, CEOZhittya Genesis Medicine, Inc.702-790-9980dan@zhittyamedicine.com

Investor Relations Contact:

Matt Glover and Tom ColtonGateway Investor Relations949-574-3860zhittya@gatewayir.com

Continued here:
Zhittya Genesis Medicine Signs $151.5 Million Biopharmaceutical Marketing Partnership Agreement with Regenerative Medicine of Latin America - BioSpace

MIAMI, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine Inc. (BPSR) (the Company) is pleased to provide shareholders and the investment community with an update on operations since its filing on November 1, 2018 of the Companys Annual Report on Form filing of Form 10-K for the year ended October 31, 2017, as well as the status of becoming fully compliant with SEC reporting obligations.

The Company is diligently working to complete its Quarterly Reports on Form 10-Q for the quarters ended January 31, 2018, April 30, 2018 and July 31, 2018 and its Annual Report on Form 10-K for the year ended October 31, 2018. In August 2019, the Company engaged Marcum LLP as its independent registered public accounting firm. The Company expects these reports to be completed and filed during the first calendar quarter of 2020. Following completion and filing of these reports, the Company expects to promptly proceed to preparation and filing of its Quarterly and Annual Reports for the fiscal year ended October 31, 2019, with the objective of becoming current in its SEC reporting requirements as soon as possible.

Since November 2018, the Company has remained focused on research and development activities and sale and distribution of anti-aging and cellular therapy derived products.

In February 2019, the Company recommenced its efforts to once again operate a perinatal tissue bank processing laboratory in Miami, Florida for the purpose of performing research and development and the manufacturing and processing of anti-aging and cellular therapy derived products. This new laboratory facility became operational in May 2019 and during the same period, the Company began producing products that are now being sold and distributed to its customers.

In addition, the Company has created what it believes is a world class research, medical and scientific advisory team. We believe that our team is one of the most qualified and industry reputable teams assembled to adequately address the current and expected future medical and regulatory challenges facing the Company and overall industry and to provide leadership in the ongoing development of superior quality products for use in the health care industry.

The Company has actively taken steps to assure that it meets compliance with current and anticipated United States Food and Drug Administration (FDA) regulations expected to be enforced beginning in November 2020 requiring that the sale of products that fall under Section 351 of the Public Health Services Act pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue based products (HCT/Ps) can only be sold pursuant to an approved biologics license application (BLA). On July 14, 2019, the Company received Institutional Review Board (IRB) approval to proceed with two pilot studies in connection with the Companys efforts to obtain Investigation New Drug (IND) approval from the FDA and commence clinical trials in connection with the use of the Companys products and related treatment protocols for specific indications. The Company is aggressively pursuing efforts to obtain the aforementioned IND approvals and commence and complete those clinical studies as well as obtaining approval to commence additional studies for other specific indications it has identified that the use of its products will provide more favorable and desired health related benefits for patients seeking alternative treatment options than are currently available.

In an effort to increase sales and mitigate anticipated near future restrictions expected to be imposed by the FDA with respect to the use and distribution of Section 351 designated biologics, the Company is seeking to develop sales and distribution channels outside of the United States. In addition, the Company is focusing its efforts on developing other leading edge product offerings that would not fall within the FDA regulations for requiring a BLA license for U.S. manufacture and sale.

As a result of the Companys expected future increase in processing requirements and to enable it to perform certain advanced research and development activities, the Company is currently in negotiations to relocate its laboratory facility during the second calendar quarter of 2020 to a larger ISO 7 classified research and development and processing facility.

Story continues

The Company has also been actively developing and expanding its sales, marketing and distribution network which it believes that based on the quality of the Companys existing products, the Companys commitment to regulatory compliance and superior research and development resources, the Company believes that it will be able to achieve desired growth during 2020.

The Company expects to provide periodic updates on operational and financial reporting developments as warranted.

For more information regarding the Company please visit our website at http://www.organicell.com.

About Organicell Regenerative Medicine, Inc.

Organicell is a leading, fully integrated Company focused in the field of regenerative medicine. Our world class research, technology, manufacturing and clinical development team is focused on creating new biologic medicines to revolutionize the field of regenerative medicine. We believe that our ground-breaking research in the field of nanotechnology, specifically exosome enrichments and other micro vesicles, is the next frontier of stem cell-based therapeutics. Organicell is committed to creating life changing and lifesaving therapies for patients.

Our mission is to transform regenerative medicine by continuing to combine exosome technology with other synergistic therapies and become the healthcare technology incubator for biologic medicine.

CAUTIONARY COMMENT REGARDING FORWARD-LOOKING STATEMENTS

The foregoing contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We intend for these forward-looking statements to be covered by the safe harbor provisions of the federal securities laws relating to forward-looking statements. This release contains forward-looking statements that reflect Organicell Regenerative Medicine Inc., and its subsidiaries, plans and expectations, financial situation, the ability to retain key personnel, product acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, ability to expand sales and channels, and legislation or regulations affecting our operations and the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties. You are cautioned not to rely on these forward-looking statements. In this press release and related comments by Company management, words like "expect," "anticipate," "estimate," "intend", believes and similar expressions are used to identify forward-looking statements, representing management's current judgment and expectations about possible future events.

Management believes these forward-looking statements and the judgments upon which they are based to be reasonable, but they are not guarantees of future performance and involve numerous known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, achievements or financial position to be materially different from any expressed or implied by these forward-looking statements. Important factors that could cause actual results to differ materially from the forward-looking statements are set forth in our Form 10-K and other filings with the SEC. Other information can be obtained at http://www.organicell.com. The contents of the Companys website are not incorporated by reference in this Press Release.

Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press releases.

CONTACT:Organicell Regenerative Medicine Inc.4045 Sheridan Ave.Suite 239Miami Beach, FL 33140Website:http: http://www.organicell.comPhone: (888) 963-7881Email: info@organicell.com

See original here:
Organicell Regenerative Medicine Inc. Provides Update On Operations and Financial Reporting Status - Yahoo Finance

Transaction Accelerates Anikas Revenue Growth, Broadens Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities and Expands Pipeline

BEDFORD, Mass., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.(ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietaryhyaluronic acid (HA) technology platform, today announced it has closed its acquisition of Parcus Medical, a leading, privately held sports medicine company.

Under the previously disclosed terms of the agreement, Anika acquired all outstanding membership interests of Parcus Medical in exchange for an upfront payment of approximately$35 millionin cash from the companys existing balance sheet, subject to customary closing adjustments. Parcus Medical unitholders will be eligible to receive an additional$60 millioncontingent upon the achievement of certain commercial milestones.

I want to congratulate our team on closing the Parcus Medical transaction and officially welcome the Parcus Medical team to the Anika family, said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. This acquisition immediately adds a diverse base of high-growth revenue and will help us achieve the objectives we set forth in our five-year strategic plan. We can now turn our attention to executing our integration plan and continuing to transform Anika into a leading global sports and regenerative medicine company.

Parcus Medical has a diverse product family that helps facilitate surgical procedures on the shoulder, knee, hip and distal extremities. The acquisition significantly expands Anikas offerings into the fast-growing ambulatory surgical center market. The Parcus Medical executive team, led by PresidentMark Brunsvold, will join Anika and continue to lead the Parcus Medical business.

SVB Leerink LLCacted as exclusive financial advisor to Anika andSullivan & Cromwell LLPacted as Anikas legal counsel in connection with the Parcus Medical transaction.

AboutAnika Therapeutics, Inc.Anika Therapeutics, Inc.(ANIK) is a global, integrated joint preservation and regenerative therapies company based inBedford, Mass.Anika is committed to delivering therapies to improve the lives of patients across a continuum of care from osteoarthritis pain management to joint preservation and restoration. The company has more than two decades of global expertise commercializing more than 20 products based on its proprietaryhyaluronic acid (HA) technology platform. For more information about Anika, please visitwww.anikatherapeutics.com.

Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, concerning, but not limited to, the acquisition of Parcus Medical and the effects of the acquisition.The Securities and Exchange Commission("SEC") encourages companies to disclose forward-looking statements so that investors can better understand a companys future prospects and make informed investment decisions. Forward-looking statements are subject to risks and uncertainties, many of which are outside our control, which could cause actual results to differ materially from these statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements can be identified by such words as "will," "likely," "may," "believe," "expect," "anticipate," "intend," "seek," "designed," "develop," "would," "future," "can," "could," and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans, and objectives are forward-looking statements.

Follow this link:
Anika Therapeutics Closes Acquisition of Parcus Medical - Yahoo Finance

Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, today announced their presentation of a poster, titled Five year follow-up on the first-in-human transplantation of undifferentiated stem cells into Parkinsonian patients reveals no adverse effects with improvement in motor function or arrest of the disease progression in five out of seven patients, at the Phacilitate Leaders World and World Stem Cell Summit, held January 21-24 in Miami, Florida.

The poster shows five-year follow-up data that expands on the exploratory clinical data in 7 PD patients with four-year follow-up published in Cell Transplantation in 2018. Oleg Kopyov, Executive Vice President and Chief Scientific Officer at Celavie, presented the poster on-site at the Miami Hyatt Regency.

In the results at one year after cell grafting, all but two of the seven patients completing the study showed various degrees of motor improvement, and five of them showed better response to medication. At five-year evaluation, Unified Parkinsons Disease Rating Scale III (UPDRS III) scores remained better than at baseline in 4/7 patients in the OFF condition and in 5/7 patients in the ON condition. None of the patients showed unwanted motor disturbances (dyskinesias), tumor formation, or any detectable immune responses to the grafted cells.

We are excited that the five-year data for our exploratory clinical trial suggest that the neural progenitor cells are able to stop or slow down the motor deterioration in Parkinsons patients that one would expect to see in this timespan, showing continued improvement even compared to the fourth year, said Oleg Kopyov. We anticipate filing an IND with the FDA for a Phase I U.S. trial in patients with moderate to advanced Parkinsons disease this year.

In addition, Sandy Solmon, Celavies CEO, will deliver presentations at two upcoming international industry conferences:

Ms. Solmon will discuss Celavies application of the companys human undifferentiated allogeneic pluripotent stem cells in Parkinsons disease, as well as pre-clinical data in cerebellar ataxia and upcoming milestones. To schedule a meeting with Celavie Biosciences at these conferences, please contact: Mary Beth Cicero at mbcicero@lavoiehealthscience.com.

About the World Stem Cell Summit

Produced by the non-profit Regenerative Medicine Foundation (RMF), and in its 15th year, the World Stem Cell Summit will take place January 21-24, 2020, in Miami, Florida in partnership with Phacilitate Leaders World, as part of Advanced Therapies Week. The Summit is the most inclusive and expansive interdisciplinary, networking, and partnering meeting in the stem cell science and regenerative medicine field. With the overarching purpose of fostering translation of biomedical research, funding, and investments targeting cures, the Summit and co-located conferences serve a diverse ecosystem of stakeholders. For more information about the upcoming World Stem Cell Summit in Miami, please visit: http://www.worldstemcellsummit.com.

About Celavie Biosciences

Celavie Biosciences is a privately-held company whose mission is to improve lives and restore hope by advancing regenerative stem cell therapies for the treatment of Parkinsons disease and other disorders of the central nervous system (CNS). The company develops undifferentiated, unmodified allogeneic pluripotent stem cell-based therapies, holds a strong IP portfolio, including 18 issued patents, and has an experienced management team blending expertise in concept and cell technology, product scalability and entrepreneurship. Celavet, a subsidiary, applies the same proprietary technologies for the treatment and prevention of serious veterinary diseases. More information is available at https://www.celavie.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200122005497/en/

View original post here:
Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit - Financialbuzz.com

Manufacturing issues and a scarcity of new commercial products leave predictions that 10-20 cell and gene therapy approvals each year by 2025 somewhat fanciful, says Dark Horse Consulting.

In his plenary address at the Phacilitate conference yesterday, Anthony Davies, founder of cell and gene therapy specialist firm Dark Horse Consulting, reflected on the difficulties the sector has faced since the high of 2017 when three products achieved US Food and Drug Administration (FDA) approval: Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), and gene therapy Luxturna (voretigene neparvovec).

A few years ago, I introduced this evening by saying: Finally the field has had the year that weve been saying we are going to have for years. That was a great year, he told the packed room in Miami, Florida.

Dark Horses Anthony Davies opened the Phacilitate conference in Miami, Florida

The CAR-T therapies Kymriah and Yescarta gave hope to patients who previously could measure their life expectancy in a small number of months, while gene therapy Luxturna offered hope to children whose ophthalmic deterioration was a statistical certainty, he added.

With these breakthroughs, positivity was high and in January 2019 then FDA Commissioner Scott Gottlieb predicted in an agency statement that there will be upwards of 200 regenerative medicine IND submissions from 2020, and by 2025 the agency will be approving 10 to 20 cell and gene therapy products a year.

I think 200 INDs is doable this year, but INDs do not cure patients, Davies said. And I think if weve struggled with getting three commercial approvals in the years after that first year when three commercial approvals were made, so getting 10-20 in five years from now is going to be extremely challenging.

Since that breakthrough year, the industry has been hot by bad news and a lack of commercial products. Novartis/AveXis Zolgensma (onasemnogene abeparvovec) and bluebirds Zynteglo (autologous CD34+ cells encoding A-T87Q-globin gene) were approved by the FDA last year, while Takedas allogeneic cell therapy Alofisel (darvadstrocel) has been approved to a certain extent in Europe.

While Davies described the approval of Zolgensma, at a cost of $2.1 million, as groundbreaking, he noted it has been overshadowed by a scandal involving data falsification during the approval process.

He also noted that Zynteglos success has been muted by multiple manufacturing problems which has delayed launch.

Meanwhile, pioneer product Kymriah continues to suffer from manufacturing difficulties, and Novartis seems to be struggling with fixing them, Davies suggested.

At JP Morgan [Healthcare Conference] it was announced that for 10% of patients no shipment of drug is made, and for a very significant minority of patients shipment is made with out-of-spec product for which Novartis cannot charge, he told the conference

He added that at the investor conference last week, Novartis CEO Vasant Narasimhan said that they had made great process in identifying the manufacturing issues and were negotiating their resolution with the FDA.

This was exactly the same statement he made at JP Morgan the year before that.

But despite the slowdown in commercialization and industrys challenges, Davies said there remains a lot to be positive about.

Everything that I said reflects the extreme difficulty in bringing this class of therapeutics to market. If these therapeutics were easy to develop,p they would have been developed. If diseases were easy to cure, we wouldnt need new therapeutics.

Let us just use these good pieces of news and these bad pieces of news as inspiration, lets continually remind ourselves that what we do is one of the hardest things in science or medicine at this time.

Davies was not alone in his views.

Speaking Wednesday, Robert Preti, CEO of Hitachi Chem Advanced Therapeutic Solutions, admitted the industry is behind where he thought it would be when he began his career 37 years ago, but said he was not too worried.

I want to commend this industry on what we have achieved for patients, he said, noting the difficulty in developing and making these therapies. He also highlighted that with over 1,000 regenerative therapies in development, problems will eventually be ironed out and cell and gene therapies will make the widespread impact intended.

More here:
FDA cell and gene therapy forecast 'unlikely' - Bioprocess Insider - BioProcess Insider

Regenerative Medicine report is a comprehensive analysis of global market has newly added by Healthcare Intelligence Markets to its extensive repository. The statistical report offers a prime wellspring of applicable information for global business progress.

Regenerative Medicine research reports growth rates and market value based on market dynamics, growth factors. Complete knowledge is based on the latest innovations in the industry, opportunities and trends. In addition to SWOT analysis by key suppliers, the report contains a comprehensive market analysis and major players landscape.

Ask for Sample Copy of This Report: https://www.healthcareintelligencemarkets.com/request_sample.php?id=135675

Top Key Players Profiled in This Report: DePuy SynthesMedtronicZimmerBiometStrykerAcelityMiMedx GroupOrganogenesisUniQureCellular Dynamics InternationalOsiris TherapeuticsVcanbioGamida CellGolden MeditechCytoriCelgeneVericel CorporationGuanhao BiotechMesoblastStemcell TechnologiesBellicum Pharmaceuticals

The key questions answered in the report:

1. What will be the market size and growth rate in the forecast year?

2. What are the key factors driving the Regenerative Medicine?

3. What are the risks and challenges in front of the market?

4. Who are the key vendors in the Regenerative Medicine?

5. What are the trending factors influencing the market shares?

6. What are the key outcomes of Porters five forces model?

7. Which are the global opportunities for expanding the Regenerative Medicine?

The purpose of this study is to define the overview of the Regenerative Medicine with respect to market size, shares, sales patterns, and pricing structures. Primary and secondary research refer collect the desired data of the target market. Different global regions such as North America, Latin America, Asia-Pacific, Africa, and the Middle East are examined to evaluate the facts about productivity.

Get Discount on This Report: https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=135675

Reasons for buying this research report:

Identification of key factors instrumental in changing the Regenerative Medicine scenario, exploiting new opportunities, and gaining competitive edge.

Analyzing various perspectives of the market with the help of Porters five forces analysis.

End-user industry that is likely to witness highest adoption of these Regenerative Medicine.

Regions that are expected to witness the fastest growth during the forecast period.

Finally, researchers throw light on pinpoint analysis of Regenerative Medicine dynamics. It also measures the sustainable trends and platforms which are the basic roots behind the market growth. The degree of competition is also measured in the research report. With the help of SWOT and Porters five analysis, the market has been deeply analyzed. It also helps to address the risk and challenges in front of the businesses. Furthermore, it offers extensive research on sales approaches.

If You Have Any Query, Ask Our Experts: https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=135675

Table of Contents:

Chapter 1: Regenerative Medicine OverviewChapter 2: Global Economic Impact on IndustryChapter 3: Market Competition by ManufacturersChapter 4: Production, Revenue (Value) by RegionChapter 5: Supply (Production), Consumption, Export, Import by RegionsChapter 6: Production, Revenue (Value), Price Trend by TypeChapter 7: Regenerative Medicine Analysis by ApplicationChapter 8: Manufacturing Cost AnalysisChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Regenerative Medicine Forecast

Marvella Lit

View all posts byMarvella Lit

Excerpt from:
Regenerative Medicine Market Market 2020 | Trends, Segmentation, Applications and Opportunities Forecasts To 2027 - VOICE of Wisconsin Rapids

By Robin Young andNicole ClarkSUN Columnist

Ever noticed how the onset of winter weather tends to increase the frequency of illness? While weather does play a role, it is not the direct cause. Rather, place blame on the true culprits causing your illness; for example rhinovirus (common cold) and influenza virus (flu).

The connection between winter and illnessThe connection lies in the fact that cold, dry weather is the preferred environment for pathogens to replicate and thrive. Consequently, your body is exposed to more germs during winter. Aside from heading south when temperatures drop, your next best bet is to prepare for battle. Fortunately, with the right support, your body is equipped with a highly efficient immune system.

Your immune system in a nutshellThis defense system is composed of many specialized cells, which are generally referred to as white blood cells. The first responsibility of immune cells is to recognize foreign pathogens in your body. Once recognized, the next step is to destroy them. Finally, your immune cells memorize the pathogen in order to destroy it quickly upon the next exposure. Coordinating this effort is a full-time job, requiring immune cells to function at the top of their game.

Support your hardworking immune systemSupport for your immune system includes everything from diet to physical activity to hygiene. Here are a few suggestions on what you can do and why it works.

Vitamin DEat or consume foods high in vitamin D, which helps your immune cells recognize unwanted bacteria.Considerable controversy exists among health professionals regarding the definition of vitamin D deficiency. Consult with your provider for information specific to you.Eat 3 ounces of fish one to three times a week. Fish such as salmon, herring, tuna and trout are good sources of dietary vitamin D.Incorporate mushrooms into your diet. Mushrooms are a great source of vitamin D and phytochemicals, both of which support your immune system.Try adding mushrooms to soups, sauces and casseroles. The water in these dishes extracts the phytochemicals found in mushrooms such as button, oyster and shiitake.Other good sources of vitamin D include fortified dairy milk, plant-based milk or juices.

Move your bodyShort bouts (15 minutes) of moderate-intensity exercise help boost immune function.Moderate intensity means you are breathing harder than normal, but can still talk.

Early to bed, later to riseDuring sleep, the body not only produces immune cells, but also enhances existing cells ability to quickly respond to disease-causing microorganisms known as pathogens.Aim for seven to nine hours when you are feeling well.

Feed gut microbes with fiberComplex carbohydrates such as those found in lentils, beans, barley and oats (to name a few) feed the bacteria in your gut.Gut microbes convert complex carbs to short-chain fatty acids that, once absorbed, help immune cells recognize and destroy pathogens.Plus, short-chain fatty acids strengthen the epithelial cells lining your intestine, thus improving your natural barrier to pathogens.

Wash your hands frequentlyThe best defense starts externally.Prevent the introduction of pathogens into your mouth or nose by washing hands often.

If all else failsIf all else fails, rest, recover, hydrate and stay warm.Contrary to human tendency, when you begin to feel ill, the quickest route to recovery means taking some down time, no matter how busy you are.

Upcoming eventsJanuary/February: Support your local 4-H Program by purchasing soup from a 4-H member.Feb. 11: The 36th annual Beef Symposium will be held at the Archuleta County Extension office. The cost is $25 per person and includes lunch. Please call the Extension office at 264-5931 for more information and to register.Feb. 12: The Agricultural Financial Management Strategies workshop, hosted by the CSU Agriculture and Business Management Team, will cover topics such as risk management, business planning, enterprise budgeting, record keeping and more. Please go to http://www.2020fms.eventbrite.com to register or come into the office to pay. The cost is $15.

CPR and first aid classesCPR and first aid certification classes are offered monthly by the CSU Extension office on the second Monday and Wednesday of each month from 6 to 10 p.m. Anyone needing to receive or renew certification can register by calling the Extension office at 264-5931.We will also attempt to schedule classes on additional dates with five or more registrations. Cost for the classes is $80 for combined CPR/first aid and $55 for CPR, first aid or recertification. The type of first aid information provided will vary by the needs of the audience.

Follow these topics: Extension Viewpoints, Lifestyle, Top Stories

By Pagosa Springs SUN Online

See original here:
Extension Viewpoints: Winter weather and illness prevention - Pagosa Springs Sun

Most of us think of inflammation as the redness and swelling that follow a wound, infection or injury, such as an ankle sprain, or from overdoing a sport, "tennis elbow," for example. This is "acute" inflammation, a beneficial immune system response that encourages healing, and usually disappears once the injury improves.

But chronic inflammation is less obvious and often more insidious.

Chronic inflammation begins without an apparent cause - and doesn't stop. The immune system becomes activated, but the inflammatory response isn't intermittent, as it is during an acute injury or infection. Rather, it stays on all the time at a low level.

Experts think this may be the result of an infection that doesn't resolve, an abnormal immune reaction or such lifestyle factors as obesity, poor sleep or exposure to environmental toxins. Over time, the condition can, among other things, damage DNA and lead to heart disease, cancer and other serious disorders.

"Unlike acute inflammation, which benefits health by promoting healing and recovery, chronic inflammation is characterized by persistent increases in inflammatory proteins all throughout the body and can damage health and promote several major diseases," says George Slavich, associate professor of psychiatry and biobehavioral sciences at UCLA, referring to small proteins called cytokines that the immune system releases at the site of an injury to promote recovery.

"People typically don't know that they have chronic inflammation until it's too late," he says.

Individuals often learn they have chronic inflammation when they develop an autoimmune disease, such as Crohn's disease, lupus or Type 1 diabetes, since inflammation is a hallmark of autoimmune disorders. But experts believe chronic inflammation also plays a role in developing heart disease, cancer, kidney disease, nonalcoholic fatty liver disease, neurodegenerative disorders, cognitive decline and mental health illnesses, such as depression, post-traumatic stress disorder and schizophrenia.

Scientists are still learning about why chronic inflammation is so dangerous and how it contributes to disease. Meanwhile, they suggest actions people can take to reduce their risk, specifically by changing certain behaviors.

Numerous factors appear to raise the risk of chronic inflammation, among them social isolation, psychological stress, disturbed sleep, chronic infections, physical inactivity, poor diet, obesity and exposure to air pollutants, hazardous waste products, industrial chemicals and tobacco smoke.

Experts believe individuals can reduce their risk by adopting lifestyle changes, including eating a healthy diet, improving sleep, exercising regularly, quitting smoking and finding ways to decrease stress and exposure to environmental pollutants.

"Diet is one of the key factors that influences inflammation in the body," Slavich says. "Whereas fried foods, red meat, sodas, and white bread and pastries that have refined carbohydrates tend to increase inflammation, fruits, nuts, green leafy vegetables, tomatoes and olive oil tend to reduce inflammation. Therefore, while diet is not the only factor that can be targeted to improve immune health, it is an important one."

Scientists think chronic inflammation causes oxidative stress in the body, which is an imbalance between the production of dangerous free radicals, molecules that harm healthy tissue in the body, and antioxidants, substances that clean up waste products and neutralize them. This can damage DNA as well as proteins and fatty tissue, which in turn accelerates biological aging.

"Chronic inflammation is involved in not just a few select disorders but a wide variety of very serious physical and mental health conditions," says Slavich, senior author of a recent paper signed by scientists from 22 institutions urging greater prevention, early diagnosis and treatment of severe chronic inflammation. "Indeed, chronic inflammatory diseases are the most significant cause of death in the world today, with more than 50 percent of all deaths being attributable to inflammation-related diseases."

Researchers still don't understand the exact mechanisms of how certain behaviors influence chronic inflammation, although a few examples are clear. In heart disease, for example, cigarette smoking and air pollution irritate the arteries, which stimulates inflammation.

"The 'damage accumulation' theory is a possibility, but the reality is that we do not know whether inflammation is causing these health and functional problems, or whether it's an indication that some other process is evolving that undermines health," says Luigi Ferrucci, scientific director of the National Institute on Aging. "The evidence is clearer for cardiovascular disease, since it has been demonstrated that blocking inflammation with specific drugs prevents cardiovascular events. For the other outcomes, it's still uncertain."

Chronic inflammation can contribute to cognitive decline and mental health disorders by boosting age-related immune system deterioration, known as immunosenescence, and by promoting vascular and brain aging, which, in combination, degrade neural and cognitive function, experts say.

"Chronic inflammation can also cause threat sensitivity and hypervigilance, which gives rise to anxiety disorders and PTSD, as well as fatigue and social-behavioral withdrawal, which are key symptoms of depression," Slavich says.

Scientists say more research is needed to identify biomarkers or other substances that suggest the presence of chronic inflammation.

There are probably hundreds of these potential diagnostic tools produced by the immune system, but they remain unidentified, Slavich says.

The most widely used test measures levels of C-reactive protein (CRP) in the blood. CRP, a substance produced by the liver, rises when chronic inflammation is present, although the standard CRP test is nonspecific - that is, it indicates inflammation, but cannot pinpoint exactly where it is. A second, more sensitive test (hs-CRP) suggests a higher risk of heart attack, although it too can be imprecise.

Some doctors screen for CRP as part of routine physical exams and also among people at risk for heart disease and autoimmune conditions. Experts think wider screening could identify more patients. "This isn't a bad idea," Ferrucci says.

Another test - this one more specific to heart disease - screens for myeloperoxidase, or MPO, an enzyme released by white blood cells that kills harmful bacteria in inflamed blood vessels. Increases in MPO can be dangerous, causing further damage to arterial walls, which encourages the formation of clots. These, in turn, can block blood flow, leading to heart attack and stroke. MPO also reduces the effectiveness of HDL, the "good" cholesterol, and removes nitric oxide, which is important for the regulation of healthy blood flow.

The good news, however, is that people worried about developing chronic inflammation can take affirmative steps to prevent it.

"If we make people aware of these risk factors, our hope is that individuals will reduce the factors that apply to them," Slavich says.

More:
Chronic inflammation is dangerous, and you may not even know you have it - Burlington Times News

Most of us try our best to live a healthy lifestyle by exercising and eating right and for good reason. Maintaining our health helps ensure that our immune system, our body's defense system that protects against foreign invaders, is strong. Without a fighting immune system, we become susceptible to all sorts of infectious diseases and viruses.

Staying hydrated is one way to boost your immune system. Make it a habit to drink a glass first thing in the morning.

Credit: EmirMemedovski/E+/GettyImages

There are big things we can do to keep our immune systems healthy, including eating right, exercising and staying up-to-date with vaccines, but there are also small things we can do on a daily basis to keep our body's defense system in tip-top shape.

In that spirit, here are nine everyday microhabits that can help boost your immune system and keep your body healthy.

Even if you don't smoke, you may suffer from the damage it can cause to parts of your immune system if you are exposed to it secondhand, according to the Centers for Disease Control and Prevention.

"Chronic secondhand smoke exposure causes inflammation of both upper and lower respiratory tract and impairs the immune system's ability to produce antibodies in response to exposure to bacteria," explains Julia Blank, MD, family medicine physician at Providence Saint John's Health Center in Santa Monica, California. "This leads to decreased clearance of bacteria from the lungs and increases asthma flares, which can both make a person more vulnerable to infection."

Try to avoid places where you'll be exposed to secondhand smoke, and ask others around you to get in the habit of going outside if and when they smoke.

Protein is an essential component of a healthy immune system.

Credit: Rawpixel/iStock/GettyImages

Protein is a vital nutrient for many reasons. It helps the body build and repair tissue, and it's also the centerpiece of a healthy immune system, says Roger Adams, PhD, personal trainer, doctor of nutrition and owner of eatrightfitness.

Research, including a March 2016 study in Food & Function, has shown that protein from high-quality sources (i.e. lean meat) is essential for optimal health. "If protein intake is poor, it can impair the body's ability to make antibodies, large proteins produced by the immune system in response to the invasion of foreign molecules," Adams says. "Without sufficient protein to make antibodies, the immune system loses its ability to fight infections."

Protein can be easier to come by at lunch or dinnertime, so breakfast is the perfect meal to squeeze in more.

The American College of Sports Medicine recommends getting 0.8 grams of protein per kilogram (or 2.2 pounds) of body weight each day, but keep in mind that people who are active need more. Weight-lifters or those training for a running or cycling event should eat between 1.2 to 1.7 grams of protein per kilogram of body weight daily. To put that into perspective, a weight-lifter who weighs 170 pounds should be getting somewhere between 92 and 131 grams of protein each day.

This one might sound obvious, but too few people actually wash their hands well enough to eliminate illness-causing bacteria. In fact, one April 2013 study published in the Journal of Environmental Health observed the hand-washing behavior of nearly 4,000 people and found that as many as 95 percent don't wash their hands for a long enough time after going to the bathroom.

The Centers for Disease Control and Prevention recommends washing your hands for at least 20 seconds to minimize germ exposure and keep the immune system from getting overwhelmed.

Sing the "Happy Birthday" song twice through as you soap up your hands to make sure you're hitting the 20-second mark.

All fruits and vegetables are beneficial for our health, but some can do more for our immune system than others. The cream of the crop are the ones rich in color, as they tend to have more nutrients, Adams says.

"The more colors, the more antioxidants, which the body uses to fight off free radicals that may contribute to cellular damage," he says. "Also, these foods are loaded with vitamins and minerals essential for a healthy immune system."

Unfortunately, most people aren't getting enough. For adults, the Dietary Guidelines for Americans recommends eating two cups of brightly colored fruits and two to three cups of vibrant veggies per day. But even one extra serving will do you good.

Learn how to fill your plate with healthy, nutrient-dense foods by logging your meals on the MyPlate app. Download now to fine-tune your diet today!

Getting enough sleep can help boost your immune system.

Credit: David-Prado/iStock/GettyImages

Sleep is essential to a healthy, functioning immune system. One February 2019 study in the_ Journal of Experimental Medicine_ found that a good night's sleep can boost the efficiency of T cells in the body, a type of white blood cell that helps the body fight off viruses.

"Many people stay up late and miss the opportunity to boost their immunity by proper sleep hygiene," says Shiva Lalezar, DO, functional medicine and anti-aging specialist. "The adrenal glands, which produce cortisol (the stress hormone), epinephrine and norepinephrine, get disrupted by poor or inadequate sleep, which, in turn has a negative impact on the immune system."

In order to go to bed at a proper hour, you have to create a healthy bedtime routine, according to the National Sleep Foundation. Start by giving yourself a curfew for example, head to bed at 10 p.m. every night and avoiding stimulating activities for at least four hours prior. Just like you set an alarm to wake up in the morning, set one to remind you to start winding down for sleep.

Staying hydrated by drinking enough water on a day-to-day basis will also give your immune system a boost.

"Dry mucous membranes and cracked skin can all be areas pathogens can invade your body," says Adams. "Staying hydrated will reduce dryness in essential areas, like the mucus membranes in your nose, and give your body's natural resources a better chance at warding off pathogens."

The National Academies of Sciences, Engineering, and Medicine recommends that men drink approximately 15.5 cups and women get 11.5 cups of H2O each day. Start by downing a glass first thing in the morning to start your day on the right foot.

According to Lalezar, a shot of ginger and lemon juice a day can help reduce inflammation and boost immunity.

"Ginger is a rich antioxidant and is antibacterial, and lemon is high in vitamin C, is an antioxidant and has antiviral and antibacterial properties," she says.

She recommends pre-mixing lemon juice with two tablespoons of minced or chopped ginger and keeping it in the fridge for a few weeks. "The lemon juice will act as a preservative to keep the ginger fresh during that time."

See the article here:
7 Microhabits to Easily Boost Your Immune System - LIVESTRONG.COM

News Release

Wednesday, January 22, 2020

Findings represent progress toward an HIV cure.

In a range of experiments, scientists have reactivated resting immune cells that were latently infected with HIV or its monkey relative, SIV, in cells in the bloodstream and a variety of tissues in animals. As a result, the cells started making copies of the viruses, which could potentially be neutralized by anti-HIV drugs and the immune system. This advance, published today in two papers in the journal Nature, marks progress toward a widely accessible cure for HIV.

The new research was conducted by investigators from the Collaboratory of AIDS Researchers for Eradication (CARE) based at the University of North Carolina at Chapel Hill and from the Emory Consortium for Innovative AIDS Research (E-CIAR) in Nonhuman Primates, both funded by the National Institutes of Health. Scientists from ViiV Healthcare and Qura Therapeutics collaborated on the research. CARE is part of the Martin Delaney Collaboratories for HIV Cure Research, the flagship NIH-supported HIV cure research program. The joint efforts of scientists from a variety of specialties made the new findings possible.

A simple, safe and scalable cure for HIV is an aspirational goal that, if achieved, would accelerate progress toward ending the HIV pandemic, said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, part of NIH. These new findings help sustain our cautious optimism that an HIV cure is possible.

While consistent antiretroviral therapy (ART) maintains the health of people living with HIV and prevents transmission of the virus, it is not a cure. Developing an HIV cure has been extremely difficult due to the persistence of viral reservoirs, where the virus hides from the immune system. These reservoirs consist of HIV-infected cells containing HIV genetic material that can generate new virus particles if a persons treatment is interrupted. The cells have entered a resting state that they maintain until they are activated to produce the virus. The immune system cannot recognize and kill HIV-infected cells in a resting state, and ART has no effect on them.

Consequently, scientists have been attempting to activate the HIV reservoir so therapeutic agents or an enhanced immune system can recognize and kill the infected cells, eliminating HIV. This strategy is often called kick and kill. Previous attempts to reactivate or kick the HIV reservoir worked well in the laboratory but were either ineffective or too toxic when tested in animals and people.

One of todays reports describes the testing of a compound called AZD5582, which belongs to a class of molecules that have proven safe as experimental cancer therapeutics.

CARE scientists obtained 20 mice with human immune systems, infected the animals with HIV, and then gave them ART that suppressed the virus. Next, the scientists injected AZD5582 into 10 of the mice and a placebo into the other 10.

Within 48 hours, high levels of HIV RNA were detected in the blood of six of the AZD5582-treated mice. HIV RNA levels in resting immune cells of the bone marrow, thymic organoid, lymph node, spleen, liver and lung were up to 24-fold higher in the AZD5582-treated mice than in the controls. This indicated that AZD5582 had activated resting cells in the HIV reservoir throughout the treated mice. The compound did not cause toxicity in the mice or activate their immune systems.

The E-CIAR and CARE investigators also obtained 21 rhesus macaques, infected them with SIV and gave them suppressive ART. More than a year after the monkeys began ART, the scientists gave 12 of them weekly intravenous infusions of AZD5582 for either three or 10 weeks.

The level of SIV increased in the blood of five of the nine monkeys (55%) that received 10 doses of AZD5582 and in none of the three monkeys that received fewer doses. Thus, SIV levels increased in five of 12 monkeys (42%) overall, even as they remained on ART. SIV RNA levels in resting immune cells from the monkeys lymph nodes were significantly higher in animals treated with 10 doses of AZD5582 than in the nine monkeys that did not receive the compound. The investigators found AZD5582 treatment to be safe for most of the monkeys. The scientists did not detect a consistent reduction in the size of SIV reservoir in the AZD5582-treated monkeys, however, suggesting that it may be necessary to pair the compound with another agent to kill activated reservoir cells.

The researchers have begun additional animal studies to determine the best dose and timing of treatment and to be sure AZD5582 activates the reservoirs of many different HIV and SIV strains. It also will be important to test other compounds in the same class as AZD5582 to determine which might work best in humans, according to the scientists. If the results of these follow-up studies are successful, a preliminary clinical trial of treatment with AZD5582 or a related compound in people living with HIV may follow.

This study was led by J. Victor Garcia, Ph.D., Ann Chahroudi, M.D., Ph.D., and Richard Dunham, Ph.D. Dr. Garcia is director of the International Center for the Advancement of Translational Science, an Oliver Smithies Investigator and a professor of medicine, microbiology and immunology at University of North Carolina at Chapel Hill. Dr. Chahroudi is an associate professor of pediatrics in the division of pediatric infectious diseases at Emory University School of Medicineand director of the Emory + Children's Center for Childhood Infections and Vaccines. Dr. Dunham is a director at ViiV Healthcare and an adjunct assistant professor at University of North Carolina at Chapel Hill.

The other new report published today describes how a combination of two agents strongly activated the SIV reservoir in ART-treated rhesus macaques and the HIV reservoir in ART-treated mice with human immune systems. One agent, an antibody called MT807R1, depletes the body of immune cells called CD8+ T cells. The other agent is an engineered protein complex called N-803, a more powerful version of a naturally occurring molecule that activates certain immune cells to fight pathogens.

E-CIAR scientists obtained 35 rhesus macaques, infected them with SIV and gave them ART, which suppressed the virus in 33 of the animals. At least a year after ART began, the scientists gave seven monkeys N-803 alone, 14 monkeys MT807R1 alone, and 14 monkeys both MT807R1 and N-803.

N-803 alone had no impact on the SIV reservoir. MT807R1 alone led to a moderate but significant increase in the level of SIV in the animals blood (their viral load). But the combination of MT807R1 plus N-803 led to a robust and persistent increase in the SIV viral load of all 14 animals even the six in which fewer than three copies of SIV were detected before the experimental treatment began.

CARE scientists at UNC replicated these outcomes in 23 mice that had been given human immune systems, infected with HIV and given suppressive ART.

In addition, investigators demonstrated in cell culture that N-803 could reactivate human immune cells latently infected with HIV, but that adding CD8+ T cells to the culture suppressed the latency-reversing activity of N-803.

Taken together, the findings illustrate that CD8+ T cells play a role in maintaining the SIV reservoir in monkeys. The scientists hope to clarify exactly how CD8+ T cells do this so they can develop a latency-reversing strategy that does not require eliminating all CD8+ T cells and is thus gentler on the body.

This research was led by Guido Silvestri, M.D. Dr. Silvestri is the Georgia Research Alliance Eminent Scholar in comparative pathology, professor and interim chair of the department of pathology and laboratory medicine at Emory University School of Medicine, and chief of the division of microbiology & immunology at Yerkes National Primate Research Center.

CARE is funded by NIAID with additional support from the National Institute on Drug Abuse, the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke, all part of NIH. E-CIAR is also funded by NIAID with additional support from the NIH Office of Research Infrastructure Programs.

NIAID conducts and supports research at NIH, throughout the United States, and worldwide to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

CC Nixon, M Mavigner et al. Systemic HIV and SIV latency reversal via non-canonical NF-B signalling in vivo. Nature DOI: 10.1038/s41586-020-1951-3 (2020).

JB McBrien et al. Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells. Nature DOI: 10.1038/s41586-020-1946-0 (2020).

###

Read more:
supported scientists reverse HIV and SIV latency in two animal models - National Institutes of Health

MEDIA CONTACT

Available for logged-in reporters only

Expert Pitch

MEDICINE

Pavel Volchkov heads the Genome Engineering Lab at the Moscow Institute of Physics and Technology (MIPT), that has several key projects, all of them involving genome editing mediated by the CRISPR/Cas technology. Discovered just a few years ago, CRISPR/Cas has emerged as one of the hottest scientific trends.

Thename of the coronavirus has to do with its distinctive crownlike shape, which you can observe with an electron microscope. [Corona is the Latin for crown.] Although sequencing reveals that the virus is closely related to a particular family, and there is a trend in virusology to abandon morphology-based names, we still use the old terminology.

The novel 2019 coronavirus or nCorona-2019 is very similar to the other coronaviruses. Itis particularly closely related to the SARS virus, which was behind the 2002-2003 severe acute respiratory syndrome outbreak in China, as well as to the Middle East respiratory syndrome, MERS.

The genome of nCorona-2019 is encoded in RNA and is notably larger than that of is peers, enabling the virus to carry not just the necessary genes but supplementary ones as well. This allows the disease to hijack a host cell, reprogram it, and even disrupt the alarm signal alerting the immune system. Since its genome is contained in an RNA molecule, the coronavirus can mutate rapidly to adapt to new conditions. That includes evading the immune response. Unlike its DNA-based cousins, the RNA virus can also quickly synthesize the proteins it needs.

A virus normally does not seek to kill its host. On the contrary, it is favorable for the virus to reproduce and use the host for as long as possible. However, besides endowing it with the ability to infect humans, the combination of mutations acquired by nCorona-2019 has made it highly immunogenic. This does not necessarily end well for the host, because the side effects of a runaway immune system might prove lethal. Evidently, that can happen with the new coronavirus. Patients may get complications in the form of pneumonia. It is the response of the immune system to a respiratory infection, sometimes leading to lung failure and possibly death.

Confirmed patients are treated by a well-timed suppression of the inflammatory processes, until the immune system can cope with the infection. The outbreak in China has to do with the extremely high population density in the central parts of the country and the climate that is favorable for such viruses. An added factor is Chinas traditional cuisine, which originated in the tough times when most of the population had to abide by the rule of If it moves, eat it. If not, wiggle it. Preliminary data suggest that the new coronavirus might have been passed to humans from snakes, which are a traditional treat in the region. This is not yet confirmed, though.

As of now, quarantine isolation is the main measure for preventing the spread of the disease. The Chinese government has shut down local passenger transportation in the affected regions. However, the virus has escaped China, and public health watchdogs around the world are monitoring the situation at state borders. Rospotrebnadzor [the agency responsible for the countermeasures in Russia] has taken the necessary steps. Namely, rapidly identifying and localizing the virus carriers. The situation calls for attention to everyone closely contacting the infected individuals, because the incubation period can last several days or more. All incoming passengers from China and other Asian countries therefore need to register and disclose their whereabouts to Rospotrebnadzor for the duration of the nCorona-2019 incubation period.

Original post:
Russian expert is ready to comment on the coronavirus - Newswise